Watch BVS. Know when insiders buy.
One email the day a filing lands. Free.
BVS
Bioventus Inc.
13.63
−0.20 −1.45%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
72
PASS · shorts 72
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E 17.7DIV YIELD —FCF YIELD —REV TTM $581.8M +3.1%NET INCOME $54.5MNET DEBT $328.2M52W 6.51 – 15.26SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 27 | $153.2M | +3.8% | 69.0% | $19.1M | $33.4M | +348.3% | 0.47 | $19.9M | $960K | $18.9M | Aug 5 |
| Q1 2026 · Mar 28 | $132.1M | +6.6% | 68.7% | $8.4M | $3.1M | — | 0.04 | $8.9M | $574K | $8.4M | May 6 |
| Q4 2025 · Dec 31derived | $157.9M | +2.8% | 68.9% | $19.5M | $14.8M | — | 0.21 | $38M | $580K | $37.4M | Mar 5 |
| Q3 2025 · Sep 27 | $138.7M | −0.2% | 68.0% | $11.3M | $3.2M | — | 0.05 | $30.1M | $473K | $29.6M | Nov 4 |
| Q2 2025 · Jun 28 | $147.7M | −2.4% | 69.1% | $18.4M | $7.5M | — | 0.11 | $25.9M | $683K | $25.3M | Aug 5 |
| Q1 2025 · Mar 29 | $123.9M | −4.3% | 67.0% | $4.9M | −$2.6M | — | -0.04 | −$19.3M | $826K | −$20.2M | May 6 |
| Q4 2024 · Dec 31derived | $153.6M | +13.5% | 66.8% | $7.7M | −$388K | — | 0.00 | $19.3M | $574K | $18.7M | Mar 5 |
| Q3 2024 · Sep 28 | $139M | +15.0% | 67.3% | $3.6M | −$5.2M | — | -0.08 | $10.3M | $64K | $10.3M | Nov 4 |
| Q2 2024 · Jun 29 | $151.2M | — | 68.5% | −$31.5M | −$25.7M | — | -0.40 | $15.2M | $77K | $15.1M | Aug 6 |
| Q1 2024 · Mar 30 | $129.5M | — | 68.3% | $4.9M | −$4.9M | — | -0.08 | −$6M | $291K | −$6.3M | May 6 |
| Q4 2023 · Dec 31derived | $135.4M | — | 63.7% | $1.2M | −$6.1M | — | -0.09 | $10.4M | $369K | $10M | Mar 5 |
| Q3 2023 · Sep 30 | $120.8M | — | 65.3% | $2.4M | −$7.3M | — | -0.12 | −$8.3M | $2M | −$10.4M | Nov 5 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $568.1M | 68.3% | $54M | $22.7M | 4.0% | 0.33 | $74.7M | $2.6M | $72.1M | — | — |
| FY2024 · to Dec 31 | $573.3M | 67.7% | −$15.2M | −$36.1M | -6.3% | -0.56 | $38.8M | $1M | $37.8M | — | — |
| FY2023 · to Dec 31 | $512.3M | 64.1% | −$81.7M | −$156.2M | -30.5% | -2.49 | $15.3M | $7.4M | $8M | — | — |
| FY2022 · to Dec 31 | $512.1M | 64.6% | −$167.2M | −$158.7M | -31.0% | -2.59 | −$13.5M | $1.5M | −$15M | — | — |
| FY2021 · to Dec 31 | $430.9M | 70.3% | $12.1M | $19.4M | 4.5% | -0.15 | $23M | $13.5M | $9.5M | — | — |
| FY2020 · to Dec 31 | $321.2M | 72.7% | $21.2M | $16.4M | 5.1% | — | $71.8M | $16.6M | $55.2M | — | — |
Every number comes from Bioventus Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.